Medically Reviewed
This article has been reviewed by Dr. Ajit Jha, MBBS, MD Medicine, IMA Lifetime Member. Content is for informational purposes only and does not constitute medical advice. Always consult your doctor before making health decisions.
When tirzepatide (Mounjaro/Zepbound) was approved, it was described as a dual GLP-1/GIP receptor agonist. Most of the attention went to GLP-1 — the hormone semaglutide (Ozempic) also targets, and the one that has dominated obesity medicine for five years. GIP was the mysterious second ingredient. Why does it matter? What does it actually do? And why does targeting two receptors instead of one produce 5–6 percentage points more weight loss? The science behind GIP turns out to be more interesting than most coverage has suggested.
📋 Key Takeaways
- GIP (glucose-dependent insulinotropic polypeptide) is released by the small intestine after meals — older than GLP-1 and historically overlooked
- GIP receptors are expressed on fat cells — GIP directly enhances fat breakdown and reduces fat storage in adipose tissue
- Tirzepatide's GIP component appears to make fat cells more responsive to GLP-1, creating synergistic — not just additive — effects
- Paradoxically, blocking GIP in rodents causes weight loss — but activating GIP in humans also causes weight loss; the biology is dose-dependent and context-dependent
- GIP also acts on bone, kidneys, and the heart — explaining some of tirzepatide's non-weight benefits
The Two Gut Hormones: GLP-1 vs GIP
Both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretins — hormones released from the gut in response to food intake that amplify insulin secretion. But their origins, receptors, and downstream effects differ significantly.
GLP-1 is released from L-cells in the lower small intestine and colon. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and — critically — acts on the brain to reduce appetite. This appetite-suppression effect via the hypothalamus is the primary mechanism behind GLP-1 drugs' weight loss effect.
GIP is released from K-cells in the upper small intestine — earlier in the digestive process than GLP-1. It was discovered first, in 1970, and for decades was considered the less important incretin. It also stimulates insulin secretion, but was thought to have minimal effect on appetite. That picture has changed dramatically in the last decade.
What GIP Actually Does in Fat Cells
The underappreciated discovery is that GIP receptors are highly expressed in adipose tissue (fat cells). GIP signalling in fat cells has direct metabolic consequences:
- Enhances lipolysis — GIP promotes the breakdown of stored triglycerides within fat cells, releasing fatty acids for energy use
- Reduces lipid storage — GIP signalling reduces the activity of lipoprotein lipase (LPL), the enzyme that stores circulating fat into adipose tissue
- Improves adipocyte insulin sensitivity — Fat cells with active GIP receptors are more responsive to insulin, improving the metabolic function of adipose tissue rather than just reducing its quantity
- Anti-inflammatory effect on fat tissue — GIP reduces adipose tissue inflammation, which is a driver of systemic insulin resistance in obesity
These adipose-specific effects explain why tirzepatide produces a higher proportion of fat loss relative to muscle loss compared to semaglutide alone — the GIP component targets fat tissue directly.
The Paradox: Why Blocking GIP Also Causes Weight Loss in Rodents
One of the more confusing aspects of GIP biology is this: in rodent studies, both activating GIP receptors AND blocking them causes weight loss. How can opposite interventions produce the same outcome?
The leading explanation is that GIP's effect on weight depends on metabolic state. In obese, insulin-resistant animals, GIP signalling promotes fat storage — blocking it therefore reduces fat accumulation. But in the context of a drug like tirzepatide, where GLP-1 signalling is also strongly activated, GIP has a different effect: it appears to enhance the sensitivity of fat cells to GLP-1's signals, amplifying fat breakdown rather than storage.
This context-dependency is why GIP research is so complex — and why the net effect of tirzepatide's combined activation turned out to be more powerful than researchers initially expected.
Synergy, Not Just Addition: Why 1+1=3 in Tirzepatide
The most important mechanistic insight from tirzepatide's clinical data is that the drug's effect appears to be synergistic, not merely additive. If you added the weight loss from a pure GLP-1 drug and a pure GIP drug, you would predict a certain amount of total loss. Tirzepatide consistently produces more than that predicted sum.
The proposed mechanism: GIP receptor activation upregulates GLP-1 receptors on key brain and fat cells, making those cells more sensitive to GLP-1 signalling. Tirzepatide then provides abundant GLP-1 stimulation to these newly sensitised receptors — creating a multiplicative effect on appetite suppression and fat metabolism.
This also explains why tirzepatide produces results that some researchers describe as approaching those of bariatric surgery — 20%+ body weight loss in clinical trials, with some patients losing over 25%.
GIP Beyond Weight Loss: Bone, Kidney, and Heart Effects
GIP receptors are found throughout the body — not just in fat tissue and the pancreas. Tirzepatide's GIP activity produces several effects beyond weight loss:
- Bone health — GIP is a potent bone anabolic signal. GIP receptors on osteoblasts (bone-building cells) stimulate bone formation. Tirzepatide may therefore have bone-protective effects not seen with GLP-1 drugs alone — particularly important given that rapid weight loss from any cause can reduce bone density
- Kidney function — GIP receptors in the kidney affect sodium and fluid handling. Tirzepatide's renal effects are under active investigation; early data shows kidney function preservation similar to semaglutide
- Cardiovascular effects — GIP receptors on cardiac cells modulate post-ischaemic recovery. The SURPASS-CVOT cardiovascular outcomes trial for tirzepatide is ongoing; early safety data shows no adverse cardiovascular signals
The GIP Story in the Indian Context
Indian patients with type 2 diabetes have been found in some studies to have lower incretin response to meals compared to Caucasian populations — meaning both GLP-1 and GIP are released in smaller amounts after eating. This impaired incretin response is one contributor to the high rates of diabetes in Indians even at lower BMI levels.
A drug that directly activates both GIP and GLP-1 receptors — bypassing the body's own impaired incretin release — may therefore be particularly beneficial for Indian patients with diabetes and obesity. This is an area of active research that has not yet been fully studied in Indian populations specifically.
Why This Matters When Choosing Between Ozempic and Mounjaro
For a patient choosing between semaglutide and tirzepatide, understanding GIP biology clarifies what tirzepatide's extra mechanism actually does:
- It targets fat cells directly — not just appetite
- It may produce more favourable fat-to-muscle loss ratio
- It amplifies GLP-1 sensitivity, creating a synergistic effect
- It offers potential bone and metabolic benefits beyond weight loss
The flip side: tirzepatide's dual action does not appear to cause substantially more gastrointestinal side effects than semaglutide — the GIP component does not worsen nausea and may even marginally reduce it by partially counteracting GLP-1's gastric emptying effects.
Dr. Ajit Jha's Clinical Perspective
“When I explain tirzepatide to patients, I avoid going deep into the GIP mechanism because it can confuse the conversation. But I do tell them this: Mounjaro targets two hunger-regulating pathways instead of one, and it hits fat cells directly in a way Ozempic does not. Patients on tirzepatide tell me their appetite control feels 'different' — less of the nausea-driven food aversion that some patients experience on Ozempic, and more of a genuine reduction in hunger and cravings. Whether this is the GIP component at work, I cannot say for certain — but it is consistent with what the mechanism predicts. For patients who have tried Ozempic with modest results, tirzepatide's additional GIP action may be what changes the equation.”
— Dr. Ajit Jha, MBBS, MD Medicine, IMA Lifetime Member
Frequently Asked Questions
What does GIP stand for?
GIP stands for glucose-dependent insulinotropic polypeptide. It is a hormone released from the upper small intestine after eating, primarily in response to fat and carbohydrate intake. It was the first incretin hormone discovered, though GLP-1 received far more pharmaceutical attention until tirzepatide changed the landscape.
Why is tirzepatide more effective than semaglutide for weight loss?
Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GLP-1 activation reduces appetite via the brain and slows gastric emptying. GIP activation targets fat cells directly — enhancing fat breakdown and reducing fat storage — and appears to sensitise fat cells to GLP-1 signalling, creating a synergistic effect. The result is an average of 20–21% body weight loss vs 15% with semaglutide.
Does GIP cause weight gain?
GIP has context-dependent effects. In obese, insulin-resistant rodents, GIP promotes fat storage — blocking it causes weight loss in those models. But in humans treated with tirzepatide (where GLP-1 activation is also present), GIP contributes to weight loss by targeting fat cells and enhancing GLP-1 sensitivity. The net human outcome is clearly weight loss, as shown in multiple large trials.
What is the SURPASS-CVOT trial?
SURPASS-CVOT is the ongoing cardiovascular outcomes trial for tirzepatide, designed to establish whether it reduces heart attack, stroke, and cardiovascular death in high-risk patients — similar to what the SELECT trial proved for semaglutide. Results are expected in 2026–2027. Early safety data shows no cardiovascular harm and preliminary signals of benefit.
📖 Related Articles